Dr. Glenn is the President of Research and Development and leads Novavax’s discovery, clinical and regulatory teams. His responsibilities include leadership of the RSV programs, including maternal immunization, and RSV F vaccine for older and high-risk adults, Nanoflu, an adjuvanted recombinant seasonal influenza vaccine, a SARS-CoV-2 vaccine for COVID-19 and other Emerging Infectious Disease vaccines.
He has spent 28 years in the design and development of vaccines, vaccine delivery, and adjuvants. He led the development of products from concept into late-stage clinical development, including RSV, recombinant adjuvanted seasonal and pandemic influenza vaccines, Ebola, and an Enterotoxigenic E. coli vaccine patch and participated in other programs including the development of Malaria vaccine. He co-founded IOMAI and provided the scientific and technical leadership that led to the acquisition by Intercell in 2008 and worked for Intercell from 2008-2010.
He has co-authored more than 100 peer-reviewed scientific publications.
Dr. Glenn was board certified and practiced pediatrics prior to completing a Medical Research Fellowship at the Walter Reed Army Institute of Research where he continued as a clinician-researcher prior to entering into commercial vaccine development in 1997.
Dr. Glenn received his Bachelor of Arts degree in Biology and Chemistry from Whitman College, Washington and his Doctor of Medicine degree from ORU School of Medicine in Oklahoma.